drugset / Trial / NCT07408193

The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.

NCT07408193

RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a randomized, double-blinded, placebo-controlled, cross-over trial examining the effect of a series of two weekly intravenous infusions of lidocaine 4 mg/kg and ketamine 0.2 mg/kg in patients with moderate to severe opioid-refractory chronic cancer-related pain. The aim of this study is to investigate whether the lidocaine - ketamine (LK) regimen provides better analgesia that an active placebo of midazolam 0.02 mg/kg, in this population.

Timeline

Start
2026-03-01
Primary completion
2027-08
Completion
2027-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 0.2 mg/kg Intravenous
Comparator Lidocaine Other / unclassified 4 mg/kg Intravenous